Inflammatory bowel disease: new insights into pathogenesis and treatment.
about
SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signalingNegative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief reviewCosts in inflammatory bowel diseasesImaging modalities for the noninvasive assessment of fibrosis in Crohn's diseaseCertolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseBritish Dietetic Association evidence-based guidelines for the dietary management of Crohn's disease in adults.Role of vitamins in gastrointestinal diseases.Differential angiogenic regulation of experimental colitis.Etanercept: a clinical review of current and emerging indications.Guidelines for the management of inflammatory bowel disease in adults.Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancementDetermination of Vitamin D Serum Levels and Status of the C3435T Polymorphism of Multidrug Resistance 1 Gene in Southeastern Iranian Patients with Ulcerative Colitis.Novel drug delivery strategies for the treatment of inflammatory bowel disease.Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model.Expression of Transcription Factor FOXO3a is Decreased in Patients with Ulcerative ColitisUlcerative colitis: diagnosis and management.Polymeric nano- and microparticle technologies for oral gene delivery.Infliximab therapy for pediatric Crohn's disease.CD83+CCR7- dendritic cells accumulate in the subepithelial dome and internalize translocated Escherichia coli HB101 in the Peyer's patches of ileal Crohn's disease.Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family.5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.Biologic targeting in the treatment of inflammatory bowel diseases.Adalimumab for the treatment of Crohn's disease.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.Importance of disrupted intestinal barrier in inflammatory bowel diseases.Immunomodulators for all patients with inflammatory bowel disease?The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.Immunosuppressive and biologic therapy for ulcerative colitis.Paediatric inflammatory bowel disease: a mechanistic approach to investigate exclusive enteral nutrition treatment.Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease.The features of intestinal tuberculosis by contrast-enhanced ultrasound.Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats.Absence of mycobacterium avium subsp. paratuberculosis in Crohn's patients.Purinergic component of mechanosensory transduction is increased in a rat model of colitis.Hepatosplenic T-cell lymphoma and TNF-α inhibitors.Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease.Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.
P2860
Q24316441-2A8429D1-B3B5-435C-8B60-25B152BDB51AQ24671928-A9B41F03-9670-4ABC-B1BE-467697617B19Q26743907-352A832D-D506-4A11-A4DD-078B95A9EAB0Q26750634-5A4A0B0B-D7EF-4033-84BE-74192492B3C5Q26998386-16549725-CEA7-4F6E-9FAA-42522BFC4234Q34449843-C4E855A6-E8AF-410D-9385-8A67B292E579Q35061688-D03446E0-C3BA-4A76-8F01-266AB275244AQ35567624-CA486F66-8018-4004-A23A-4243190DE7F9Q35569803-77164D9F-E7B3-4B76-9DB0-8ABEC75B9265Q35779227-8C79F47D-0F66-4884-A4E3-76B9CEDD1296Q35790559-2E1E145B-A982-457C-89C8-78EDDD3152B6Q35939442-A93F674B-00CE-452B-AC1F-C0EFBDE07C2DQ36306906-E13E335B-1662-4087-9D1A-773A25EC5772Q36316765-FF4CEDE3-8F88-4682-BA43-17C6CA48380DQ36316869-73F566BD-EB93-4E14-9ADF-086E630446E4Q36531919-16CF7449-F2FC-462C-81B3-3F18AA762CC3Q36562565-1CEC0246-36E0-4BFD-9006-C41A75ADD2ABQ36815912-6AA6BB59-6B77-422F-87C2-0CAFAE831148Q37012073-14FE39D7-89C2-48F2-898C-47926734338BQ37073770-4249E4AE-9B88-4987-A48B-D150CF376918Q37074042-F7439E4B-B28C-4598-88A3-FE946C576A0DQ37162453-3D48359F-3E74-49F8-8F7D-8F5101FDDC77Q37303206-FBA680A4-A6C5-4812-BE10-F0D6E4E3E7F0Q37307855-C7F3E6AC-E04E-4A92-94EB-866D3E23F2FDQ37680981-92D13327-3034-435D-91F0-550B1F98D05CQ37781315-BCB9E927-14FA-4C37-A9ED-A9F1D6B27D54Q37823320-CA1A98C6-E598-4AB0-A061-9EE8DDDAEF0CQ38044907-125D8670-CC00-45B3-990F-619EBCEAF9EAQ38060831-21756448-C0D5-4F26-A0DF-F171B2ED8742Q38223408-312A391F-B4C8-48E4-867F-8CF2B94CE966Q38659150-11EEE6A7-C377-44BC-86B7-B22E08540156Q39132618-DEE5C311-3882-4119-B6F1-A4856B8925F8Q41108985-281848B9-D1D6-44E3-9F13-EAE972FC2730Q42004558-C311FFD1-E520-4E78-970F-06F37E5E4EF2Q44714236-B3027C80-62D9-47EF-95A5-09704ADB2FC6Q45032136-B1B90A7A-A788-4530-A78D-FDCB4572D3BCQ45207777-9142FC3A-7C08-46C3-9579-E9590B3BE4FAQ45289722-F8CC40F2-933E-4D3B-8DDB-FAAA7EE8B969Q45876830-9139F547-F465-4BAE-BCCA-F6EF417C8241Q45968857-FEA35DB3-B2C1-45EE-A747-BD175825DC99
P2860
Inflammatory bowel disease: new insights into pathogenesis and treatment.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@ast
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@en
type
label
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@ast
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@en
prefLabel
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@ast
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@en
P2860
P1476
Inflammatory bowel disease: new insights into pathogenesis and treatment.
@en
P2093
Ardizzone S
Bianchi Porro G
P2860
P304
P356
10.1046/J.1365-2796.2002.01067.X
P407
P577
2002-12-01T00:00:00Z